BCM
VIVO

BlueCrest Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

BlueCrest Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,998
Closed -$179K – 1548
2018
Q3 		$179K Buy
+11,998
New +$186K ﹤0.01% 1307

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

BlueCrest Capital Management's VIVO Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q4 2018, closing a stake of 11,998 shares — an estimated $179K sold.

BlueCrest Capital Management first reported a position in VIVO in Q3 2018 and held it in 1 quarter. The position peaked at $179K in Q3 2018. 191 funds tracked by Wall St. Rank hold VIVO as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Meridian Bioscience Inc position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 11,998 Meridian Bioscience Inc shares in Q4 2018, an estimated $179K.
  • BlueCrest Capital Management first reported a position in Meridian Bioscience Inc in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Meridian Bioscience Inc position peaked at $179K in Q3 2018.
  • 191 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.